Cargando…
Chemotherapy Synergizes with Radioimmunotherapy Targeting La Autoantigen in Tumors
BACKGROUND: To date, inefficient delivery of therapeutic doses of radionuclides to solid tumors limits the clinical utility of radioimmunotherapy. We aim to test the therapeutic utility of Yttrium-90 ((90)Y)-radio-conjugates of a monoclonal antibody, which we showed previously to bind specifically t...
Autores principales: | Al-Ejeh, Fares, Darby, Jocelyn M., Brown, Michael P. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645682/ https://www.ncbi.nlm.nih.gov/pubmed/19247485 http://dx.doi.org/10.1371/journal.pone.0004630 |
Ejemplares similares
-
The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®
por: Staudacher, Alexander H, et al.
Publicado: (2014) -
APOMAB®, a La-Specific Monoclonal Antibody, Detects the Apoptotic Tumor Response to Life-Prolonging and DNA-Damaging Chemotherapy
por: Al-Ejeh, Fares, et al.
Publicado: (2009) -
Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target
por: Sabanathan, Dhanusha, et al.
Publicado: (2021) -
Radioimmunotherapy of malignancy using antibody targeted radionuclides.
por: Cobb, L. M., et al.
Publicado: (1986) -
Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors
por: Cimini, Andrea, et al.
Publicado: (2020)